Analysts rate Synaptogenix Inc. (SNPX:NSD) with a Strong Buy rating and a $11 target

STA Research rates Synaptogenix stock as Buy at a $8 SNPX stock price target.

Based on the Synaptogenix stock forecast from 2 analysts, the average analyst SNPX stock price is USD 11.00 over the next 12 months. Synaptogenix Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of SNPX stock forecast is Neutral, which is based on 1 positive signals and 1 negative signals. At the last closing, Synaptogenix stock price was USD 8.40Synaptogenix stock price has changed by +0.14% over the past week, +1.55% over the past month and +23.89% over the last year.

About Synaptogenix Inc. (SNPX:NSD):

Synaptogenix Inc. is a developing biotech company that focuses on the advancement of novel therapies for neurodegenerative diseases. The company focuses on developing a product platform for the treatment of Alzheimer’s, Autism, Sclerosis, Parkinson’s disease, strokes, and brain injuries as well as evaluating the therapeutic applications of Bryostatin. The company is actively working on the clinical restoration of cognitive functions and cerebral connections. The company was incorporated in 2012 and is headquartered in the United States.


What we like:

Superior risk adjusted returns:

SNPX stock has performed well, on a risk adjusted basis, compared to its sector peers (for a hold period of at least 12 months) and is in the top quartile.


What we don’t like:

High volatility:

The total returns for SNPX stock are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in Synaptogenix stock.